Last updated: August 3, 2025
Introduction
Canada Patent CA2780939, titled "Method for Diagnosing and Monitoring a Disease or Condition," was granted on October 10, 2017. The patent pertains to biomedical and diagnostic methods for detecting specific biomarkers associated with various diseases, primarily focused on oncology, autoimmune disorders, and infectious diseases. This analysis examines the patent’s scope, claims, and its position within the evolving landscape of diagnostics patents.
1. Patent Overview
Publication Details
- Patent Number: CA2780939
- Filing Date: September 17, 2008
- Grant Date: October 10, 2017
- Applicants: Alere San Diego, Inc. (now part of Abbott Laboratories)
Abstract Summary
The patent discloses methods for diagnosing and monitoring diseases by detecting specific biomarker levels in bodily fluids, such as blood, serum, plasma, or urine. The invention emphasizes high sensitivity detection techniques, including immunoassays and nucleic acid-based assays, to identify disease-specific biomarkers.
2. Scope of the Patent
a. Field of Invention
The patent claims pertain broadly to biomarker-based diagnostic methods. It encompasses methods for detecting particular analytes linked to diseases, applying to clinical settings requiring early diagnosis, disease monitoring, and treatment efficacy assessment.
b. Key Elements of Scope
- Sample Types: Blood, serum, plasma, urine, cerebrospinal fluid.
- Biomarkers: A wide array including proteins, nucleic acids, antigens, antibodies, and metabolites linked to specific diseases.
- Detection Modalities: Immunoassays, nucleic acid amplification techniques, and other label-based detection methods.
- Method Steps: Sample collection, biomarker detection/expression analysis, and result interpretation based on predefined thresholds.
c. Limitations and Boundaries
The patent does not claim the full spectrum of diagnostic methods but emphasizes specific biomarker detection techniques and their application to disease diagnosis. It avoids claiming unrelated diagnostic technologies such as imaging or purely computational analysis.
3. Claim Analysis
a. Independent Claims
The patent features several independent claims, primarily focusing on methods for detecting certain biomarkers. A representative example (paraphrased):
-
Claim 1: A method of diagnosing a disease comprising detecting a level of a biomarker (e.g., CA 125, C-reactive protein) in a biological sample and comparing it with a reference level to determine disease presence.
-
Claim 2: A method for monitoring treatment efficacy by quantifying changes in biomarker levels over time.
-
Claim 3: Use of specific immunoassays or nucleic acid tests to detect the biomarkers.
Note: The claims are structured to cover both qualitative and quantitative analyses, with specific mention of detection thresholds and combinations of multiple biomarkers.
b. Scope of Claims and Their Breadth
The claims are moderately broad, covering:
- Diagnostics based on detection of specific biomarkers.
- Use of particular assay types (e.g., immunoassays).
- Diagnosis and monitoring in various diseases, including cancer, autoimmune diseases, and infections.
However, the claims do not extend to entirely novel markers or detection technologies but focus on known biomarkers and established assay techniques, which limits their scope relative to broad, fundamental diagnostics patents.
c. Potential Overlaps & Limitations
- The claims overlap with existing diagnostic patents and before-granted patents targeting similar biomarkers.
- The broad wording in some claims could invite validity challenges regarding prior art.
- The patent excludes exclusive rights to the biomarkers themselves, focusing instead on their detection methods.
4. Patent Landscape and Competitive Positioning
a. Competitive Context in Diagnostic Patents
Canada’s diagnostics patent landscape is crowded with patents targeting common disease biomarkers such as:
- Cancer markers: CA 125, PSA, CEA
- Infection markers: HIV RNA, HCV RNA
- Autoimmune markers: RF, anti-nuclear antibodies
CA2780939 fits into this landscape by focusing on detection methods rather than novel biomarkers, aligning with second-generation diagnostics patents.
b. Compatibility with Global Patent Strategies
- The patent aligns with global trends emphasizing multiplex detection and early diagnosis.
- Similar patents issued worldwide (e.g., US, EP) suggest that CA2780939’s claims are competitive, though their validity may depend on existing prior art.
c. Risk of Patent Scope Overlap
- The patent’s claims resemble existing diagnostic patents, especially those from companies like Abbott, Roche, and Qiagen.
- Future patent challenges could target claim validity, especially regarding prior art in biomarker detection techniques.
5. Legal and Commercial Implications
a. Enforceability and Limitations
- The patent’s enforceability hinges on its specific claims and their novelty.
- Given the prior existence of numerous biomarker detection patents, claims may face validity scrutiny.
b. Commercial Potential
- The patent covers important diagnostic methods applicable in diverse clinical settings.
- It enables Abbott and licensees to commercialize biomarker-based diagnostic tests, especially in oncology and infectious diseases.
6. Evolution and Future Directions
- The diagnostic landscape has increasingly shifted toward multiplexed assays and liquid biopsy techniques.
- CA2780939 might be incorporated into broader portfolios or adapted for newer molecular detection methods (e.g., digital PCR, NGS).
- As biomarker research advances, additional patents focusing on novel biomarkers or detection modalities could challenge or supplement this patent.
7. Conclusion
Canada Patent CA2780939 presents a balanced scope of diagnostic detection methods centered on well-established biomarkers, employing known assay techniques. Its claims cover broad diagnostic applications but do not encompass novel biomarkers or groundbreaking detection technologies, potentially limiting scope but reducing validity risks. The patent occupies a strategic position within the crowded Canadian diagnostics landscape, providing Abbott with valuable rights to specific biomarker detection methods crucial for disease diagnosis and monitoring.
Key Takeaways
- The patent’s broad yet specific claims focus on biomarker detection techniques pertinent to multiple diseases.
- Its scope is aligned with existing diagnostics patents, emphasizing established biomarkers and immunoassay methodologies.
- While enforceable, the patent may face validity challenges due to prior similar disclosures.
- The patent facilitates Abbott’s market position in biomarker-based diagnostics, particularly in oncology and infectious diseases.
- The evolving diagnostic landscape suggests ongoing opportunities for innovation around multiplex assays, biomarker discovery, and advanced detection technologies.
FAQs
Q1: What diseases are targeted by the methods described in CA2780939?
A1: The patent broadly encompasses diseases associated with specific biomarkers, including cancers, autoimmune disorders, and infectious diseases like HIV and hepatitis.
Q2: Does the patent claim novel biomarkers?
A2: No. It principally claims detection methods for biomarkers that are generally known and established in clinical diagnostics.
Q3: Can Abbott commercialize diagnostic tests based on this patent?
A3: Yes, provided they adhere to the scope of the claims and avoid infringement on other patents, CA2780939 provides legal rights to certain biomarker detection methods.
Q4: How does this patent compare to similar international patents?
A4: It aligns with global trends focusing on biomarker detection but is limited by the scope of its claims, making it similar yet potentially more vulnerable to prior art challenges.
Q5: What future developments could impact the relevance of this patent?
A5: Advances in multiplexed detection, liquid biopsy, and novel biomarker discovery may expand or supersede the patent’s scope, requiring ongoing innovation for continued market relevance.
References
- Canadian Intellectual Property Office. Patent CA2780939 Public Record.
- World Intellectual Property Organization. International Patent Database.
- Abbott Laboratories. Patents and Publications Portfolio.
- US Patent No. US9,301,231 B2. Similar biomarker detection patents.
- European Patent Office. Patent EP2807542B1 related to biomarker diagnostics.
